9-valent HPV Vaccine
This vaccine is designed to protect against nine different types of the Human Papillomavirus (HPV), specifically types 6, 11, 16, 18, 31, 33, 45, 52, and 58. The vaccine works by stimulating the body’s immune system to produce neutralizing antibodies, which help prevent infection from these HPV types. This is particularly important for HIV-positive women, as they may be at higher risk for HPV-related complications. The study aims to evaluate the vaccine’s ability to induce a strong immune response and ensure its safety in this population.

Human Immunodeficiency Virus (HIV) Infection – HIV is a virus that attacks the body’s immune system, specifically the CD4 cells (T cells), which help the immune system fight off infections. Over time, HIV can destroy so many of these cells that the body can’t fight off infections and disease. The virus is transmitted through contact with certain body fluids of an infected person, most commonly during unprotected sex or through sharing injection drug equipment. Without treatment, HIV can gradually weaken the immune system, leading to acquired immunodeficiency syndrome (AIDS). The progression of the disease varies among individuals, but it typically involves an initial acute infection phase, followed by a chronic phase that can last for many years.

Human Papillomavirus (HPV) Infection – HPV is a group of more than 200 related viruses, some of which are spread through direct sexual contact. Certain types of HPV can cause warts on different parts of the body, while others can lead to cancers, such as cervical cancer. The virus infects the skin and mucous membranes, and many people with HPV do not develop symptoms or health problems. In most cases, the body’s immune system clears the virus naturally within two years. However, when the virus persists, it can cause cell changes that may lead to cancer over time.